Denifanstat
- Generic Name
- Denifanstat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29N5O
- CAS Number
- 1399177-37-7
- Unique Ingredient Identifier
- 4GF95B2LZA
- Background
Denifanstat is an orally bioavailable fatty acid synthase (FASN) inhibitor. Due to its antineoplastic activities, it is being investigated for various cancers.
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients with MASLD and MASH
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Sagimet Biosciences Inc.
- Target Recruit Count
- 2000
- Registration Number
- NCT06692283
A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients with MASH and F2/F3 Fibrosis
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Sagimet Biosciences Inc.
- Target Recruit Count
- 1260
- Registration Number
- NCT06594523
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2017-06-07
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 19
- Registration Number
- NCT03179904
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath